COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq:SPNC) announced today enrollment of the first patients into the TAAMI trial. The TAAMI trial (ThromboAblation in Acute Myocardial Infarction) is a planned 200-patient randomized trial involving major medical centers in Poland. Starting last quarter, TAAMI enrolled its first six patients and recently initiated the fifth participating hospital.
